Latest Financial Results

Latest Annual Report

For Fiscal Year Ending Dec 31, 2021

mail icon

Sign Up for Email Alerts

Receive updates straight into your inbox

Sign up today

Company Overview

Pieris is a clinical-stage biotechnology company that combines leading protein engineering capabilities and deep understanding into molecular drivers of disease to develop medicines that drive local biology to produce superior clinical outcomes for patients. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and locally-activated bispecifics for immuno-oncology. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by respiratory and immuno-oncology focused partnerships with leading pharmaceutical companies.

Investor Contact Information


Pieris Pharmaceuticals, Inc.
225 Franklin St., Floor 26
Boston, MA 02110
T: +1-857-246-8998

Investor Relations

T: +1-857-246-8998

Transfer Agent

P.O. Box 43006
Providence RI 02940-3078
T: 1-877-373-6374 (US, Canada, Puerto Rico) or 1-781-575-3100 (non-US)

Courier Delivery
150 Royall St.
Suite 101
Canton, MA 02021